Milestone Pharmaceuticals Inc
MIST
Company Profile
Business description
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
Contact
1111 Dr. Frederik-Phillips Boulevard
Suite 420
MontrealQCH4M 2X6
CANT: +1 514 336-0444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
38
Stocks News & Analysis
stocks
The ASX data center stock flying under the radar
While markets chase AI hype, this data centre company offers real data center earnings and a visible growth pipeline.
stocks
What did Morningstar subscribers buy and sell during June?
ETFs took centre stage in June alongside renewed interest in beaten down growth names.
stocks
Australia’s largest gold miner downgraded on a falling gold price
A cooling gold price sees fair value cuts across the board.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.60 | 16.00 | -0.18% |
| CAC 40 | 8,382.43 | 15.58 | 0.19% |
| DAX 40 | 24,999.53 | 147.50 | -0.59% |
| Dow JONES (US) | 52,617.44 | 109.17 | 0.21% |
| FTSE 100 | 10,515.92 | 13.47 | -0.13% |
| HKSE | 24,681.10 | 340.37 | 1.40% |
| NASDAQ | 26,211.48 | 104.47 | 0.40% |
| Nikkei 225 | 68,751.51 | 1,008.01 | 1.49% |
| NZX 50 Index | 13,635.07 | 16.15 | -0.12% |
| S&P 500 | 7,561.67 | 18.08 | 0.24% |
| S&P/ASX 200 | 8,841.10 | 15.90 | -0.18% |
| SSE Composite Index | 3,955.58 | 11.55 | -0.29% |